Article
GADD45α-targeted suicide gene therapy driven by synthetic CArG promoter E9NS sensitizes…
OncoTargets and Therapy · 2019 · Shi Q, Sutariya V, Varghese Gupta S, Bhatia D
Key facts
| Title | GADD45α-targeted suicide gene therapy driven by synthetic CArG promoter E9NS sensitizes NSCLC cells to cisplatin, resveratrol, and radiation regardless of p53 status |
|---|---|
| First author | Shi Q, Sutariya V, Varghese Gupta S, Bhatia D |
| Journal | OncoTargets and Therapy |
| Published | Apr 26, 2019 |
| DOI | 10.2147/OTT.S192061 |
| Devices mentioned | BK110039, K103302 |
| Product codes mentioned | KIT, NJT, OOI, PQP, NDS, PCA |
At a glance
- 1–9 FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1